GW9662
(Synonyms: 2-氯-5-硝基-N-苯基苯酰胺) 目录号 : GC13969
GW9662 is a specific inhibitor of peroxisome proliferator activated receptor-gamma (PPAR-gamma) with an IC50 of 3.
Cas No.:22978-25-2
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
|
Kinase experiment [1]: |
|
|
Preparation method |
Human PPARα, PPARγ, and PPARδ ligand binding domains (LBDs) are expressed in E. coli as polyhistidine labeled fusion proteins. In the experimental buffer, the desired receptor (15 nM) was added to the streptavitin modified SPA bead (0.5 mg/mL) pulp to fix the receptor to the SPA bead. The mixture was equilibrated at room temperature for at least 1 hour, then the beads were precipitated at 1x103g rotation speed, the supernatant was removed, the beads were gently mixed, the beads were suspended in fresh experimental buffer, the centrifugation/re-suspension procedure was repeated, the resulting acceptor coated bead slurry was used immediately, or stored at 4℃ for up to 1 week before use. Competitive binding to PPARα,PPARγ, and PPARδ was determined using [3H]GW9662 as a radioligand. Unless otherwise indicated, all experimental buffers were 50 mM HEPES (pH 7), 50 mM NaCl, 5 mM CHAPS, 0.1 mg/mL BSA, and 10 mM DTT.In some experiments, 50 mM Tris (pH 8) was used instead of HEPES(pH 7). |
|
Applications |
GW9662 is a potent and selective PPARγ antagonist with an IC50 of 3.3 nM. |
|
Cell experiment [2]: |
|
|
Cell lines |
J774A.1 cells |
|
Preparation method |
Cells were challenged with 50 ng/ml lipopolysaccharide with(or no) 10 μM GW9662 or vehicle for 18 h.Cell culture supernatant was collected, cells were lysed for RNA separation, or cells were lysed with nitric oxide synthase (NOS) buffer added with protease inhibitors, and NOS activity was measured. |
|
Reaction Conditions |
10 μM GW9662;18 h |
|
Applications |
Treatment with GW9662 significantly attenuated LPS-induced expression of Il1b, interleukin 6 (Il6) and inducible nitric oxide synthase (iNos) as well as NO2- formation. |
|
Animal experiment [3]: |
|
|
Animal models |
Male Wistar rats |
|
Preparation method |
Rats were pretreated with LPS (1 mg/kg, IP, 24 hours prior to ischemia) in the absence (control) or presence of the selective PPARγ antagonist GW9662(1 mg/kg, IP, 24 and 12 hours prior to ischemia). Twenty-four hours after injection of LPS, rats were subjected to 60 minutes of bilateral renal ischemia, followed by 6 hours of reperfusion. |
|
Dosage form |
1 mg/kg GW9662; IP;24 and 12 hours prior to ischemia |
|
Applications |
Administration of the selective PPARγ antagonist GW9662 24 and 12 hours before ischemia/reperfusion (I/R) eliminated the renal protection observed in LPS preconditioning. |
|
References: [1]. Leesnitzer LM, Parks DJ,et,al. Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662. Biochemistry. 2002 May 28;41(21):6640-50. doi: 10.1021/bi0159581. PMID: 12022867. [2].Baumann A, Burger K, et,al. GW9662, a peroxisome proliferator-activated receptor gamma antagonist, attenuates the development of non-alcoholic fatty liver disease. Metabolism. 2022 Aug;133:155233. doi: 10.1016/j.metabol.2022.155233. Epub 2022 May 30. PMID: 35654114. [3]. Collino M, Patel NS, et,al.The selective PPARgamma antagonist GW9662 reverses the protection of LPS in a model of renal ischemia-reperfusion. Kidney Int. 2005 Aug;68(2):529-36. doi: 10.1111/j.1523-1755.2005.00430.x. PMID: 16014029. |
|
GW9662 is a specific inhibitor of peroxisome proliferator activated receptor-gamma (PPAR-gamma) with an IC50 of 3.3 nM, GW9662 acts 10 to 600 times more selectively on PPARγ in cells than on PPARα and PPARδ[1-3].
Treatment with GW9662 significantly attenuated LPS-induced expression of Il1b, interleukin 6 (Il6) and inducible nitric oxide synthase (iNos) as well as NO2-formation in J774A.1 cells [4]. DMBA-induced mammary alveolar lesions (MAL) were significantly inhibited by PPARγ antagonist GW9662[5]. GW9662(2.5/5 µM) prevented disruption of the Colon carcinoma cells cycle induced by resveratrol and consequently abrogated resveratrol-induced apoptosis[6].
GW9662(p.o;3 mg/kg/day ;2 weeks) worsened the brain injury in alcohol-fed reperfusion mice[7]. Pretreatment with LPS significantly attenuated all markers of renal injury and dysfunction caused by I/R. Most notably, GW9662(1 mg/kg GW9662; IP;24 and 12 hours prior to ischemia) abolished the protective effects of LPS[8].
GW9662是一种特异性的过氧化物酶体增殖物激活受体-γ(PPAR-γ)抑制剂,其IC50为3.3 nM。在细胞中,GW9662相较于PPARα和PPARδ选择性地作用于PPARγ,选择性作用范围为10至600倍[1-3]。
使用GW9662可显著减轻LPS诱导的J774A.1细胞中Il1b、白细胞介素6(Il6)和诱导型一氧化氮合酶(iNos)的表达以及NO2-生成[4]。使用GW9662可显著抑制DMBA诱导的乳腺腺泡病变(MAL)[5]。GW9662(2.5/5µM)防止了白藜芦醇引起的结肠癌细胞周期紊乱,抵消引起的细胞凋亡[6]。
GW9662(p.o;3 mg/kg/day ;2 weeks)加剧了饮酒再灌注小鼠的脑损伤[7]。LPS预处理可显著减弱I/R引起的肾损伤和功能障碍的所有标志物。GW9662(1 mg/kg GW9662; IP;24 and 12 hours prior to ischemia)使LPS的保护效果消失[8]。
References:
[1]. Leesnitzer LM, Parks DJ, et,al. Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662. Biochemistry. 2002 May 28;41(21):6640-50. doi: 10.1021/bi0159581. PMID: 12022867.
[2]. Lea MA, Sura M, et,al. Inhibition of cell proliferation by potential peroxisome proliferator-activated receptor (PPAR) gamma agonists and antagonists. Anticancer Res. 2004 Sep-Oct;24(5A):2765-71. PMID: 15517883.
[3]. Nielsen R, GrØntved L, et,al. Peroxisome proliferator-activated receptor subtype- and cell-type-specific activation of genomic target genes upon adenoviral transgene delivery. Mol Cell Biol. 2006 Aug;26(15):5698-714. doi: 10.1128/MCB.02266-05. PMID: 16847324; PMCID: PMC1592764.
[4]. Baumann A, Burger K,et,al. GW9662, a peroxisome proliferator-activated receptor gamma antagonist, attenuates the development of non-alcoholic fatty liver disease. Metabolism. 2022 Aug;133:155233. doi: 10.1016/j.metabol.2022.155233. Epub 2022 May 30. PMID: 35654114.
[5]. Mehta RG, Peng X, et,al. PPARγ antagonist GW9662 induces functional estrogen receptor in mouse mammary organ culture: potential translational significance. Mol Cell Biochem. 2013 Jan;372(1-2):249-56. doi: 10.1007/s11010-012-1466-9. Epub 2012 Sep 24. PMID: 23001870.
[6]. Aires V, Brassart B, et,al. A role for peroxisome proliferator-activated receptor gamma in resveratrol-induced colon cancer cell apoptosis. Mol Nutr Food Res. 2014 Sep;58(9):1785-94. doi: 10.1002/mnfr.201300962. Epub 2014 Jun 30. PMID: 24975132.
[7]. Sun H, Xiong W, et,al. Low-dose alcohol consumption protects against transient focal cerebral ischemia in mice: possible role of PPARγ. PLoS One. 2012;7(7):e41716. doi: 10.1371/journal.pone.0041716. Epub 2012 Jul 27. PMID: 22848576; PMCID: PMC3407212.
[8]. Collino M, Patel NS, et,al. The selective PPARgamma antagonist GW9662 reverses the protection of LPS in a model of renal ischemia-reperfusion. Kidney Int. 2005 Aug;68(2):529-36. doi: 10.1111/j.1523-1755.2005.00430.x. PMID: 16014029.
| Cas No. | 22978-25-2 | SDF | |
| 别名 | 2-氯-5-硝基-N-苯基苯酰胺 | ||
| 化学名 | 2-chloro-5-nitro-N-phenylbenzamide | ||
| Canonical SMILES | C1=CC=C(C=C1)NC(=O)C2=C(C=CC(=C2)[N+](=O)[O-])Cl | ||
| 分子式 | C13H9ClN2O3 | 分子量 | 276.68 |
| 溶解度 | ≥ 13.75 mg/mL in DMSO, ≥ 9.08 mg/mL in EtOH with ultrasonic | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.6143 mL | 18.0714 mL | 36.1428 mL |
| 5 mM | 0.7229 mL | 3.6143 mL | 7.2286 mL |
| 10 mM | 0.3614 mL | 1.8071 mL | 3.6143 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。